RxDoctor Payments Data

Edward Hurley, MD

Cardiovascular Disease · Chesterfield, MONPI 1952522377

Payments from drug & device makers

$18,803in general payments, 2019–2025

Across 1,180 payments — averaging $15.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Boston Scientific$2K
  • Johnson & Johnson$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Pfizer$1K
  • AstraZeneca$1K
  • plus $10K from 47 others

What the payments were for

  • Consulting fees$210%
  • Food & beverage$18,62799%
  • Education$1381%
  • Entertainment$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,803 in reported general payments places this provider in the 75th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$436,602
Medicare patients
1,719
Services billed
5,246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,249$1,527,396
EntrestoSacubitril/Valsartan561$607,978
XareltoRivaroxaban403$444,482
FarxigaDapagliflozin Propanediol253$204,982
MultaqDronedarone Hcl103$174,225
Repatha SureclickEvolocumab119$97,318
VascepaIcosapent Ethyl91$58,401
JardianceEmpagliflozin37$48,732
Praluent PenAlirocumab35$23,885
NexlizetBempedoic Acid/Ezetimibe34$18,732
BrilintaTicagrelor31$18,502
LivaloPitavastatin Calcium32$18,223
NexletolBempedoic Acid21$17,862
Propafenone Hcl ErPropafenone Hcl57$13,756
Nebivolol Hcl135$11,846

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,151$1,527,3961,249 claims
NovartisEntresto$2,047$607,978561 claims
Johnson & JohnsonXarelto$1,386$444,482403 claims
AstraZenecaFarxiga, Brilinta$1,063$223,484284 claims
Sanofi-aventis U.S. LLCMultaq$585$174,225103 claims
Boehringer IngelheimJardiance$1,030$48,73237 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$540$36,59455 claims
Kowa Pharmaceuticals America, Inc.Livalo$229$18,22332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Chesterfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →